untitled

Atul Ltd | Annual Report 2010-11

Pharma & Inters

Products

APIs, API intermediates, Others

is estimated at US$ 20 bn and is growing at about 10%. There

are about 50 major companies, which dominate the world

marketplace.

The main user industry, namely, Healthcare, is growing well

because of the increasing awareness about diseases and health.

The Company along with Atul Bioscience will participate in this

growth by i) debottlenecking capacities, ii) introducing new

products and iii) significantly improving efficiencies. It will also

form long-term alliances with other companies.

Prices of many products come down significantly in a short

time. Fluctuations in foreign exchange will impact sales

realizations.

Pharma & Inters product group mainly comprises API

intermediates and a few APIs used by Pharmaceutical industry

under five broad therapeutic categories, namely, anti-

depressant, anti-diabetic, anti-infective and anti-retroviral. The

group comprises 27 products and is relatively a new introduction

to the product portfolio of Atul. The Company is not currently

engaged in formulations of APIs.

During the year, sales of the product group increased by 34% to

184 crores. Export sales increased by 43% to

95 crores and

formed 51% of the total. Atul Bioscience made its first sales,

and the Company is expected to focus only on the products

required by Pharmaceutical industry.

World market for pharmaceuticals is estimated at US$ 700 bn

and is growing at about 4%. Indian market for such products